Announcement under Rule 8.1(a) of the Irish Takeover Rules: Dealings by Offerors, Offerees or Parties Acting in Concert With Them for Themselves or for Discretionary Clients
DUBLIN, Feb. 14, 2020 /PRNewswire/ --
Ap9
APPENDIX 3
DISCLOSURE FORMS
FORM 8.1(a)&(b)(i)
IRISH TAKEOVER PANEL
DISCLOSURE UNDER RULE 8.1(a) AND (b)(i) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013
DEALINGS BY OFFERORS, OFFEREES OR PARTIES ACTING IN CONCERT WITH THEM FOR THEMSELVES OR FOR DISCRETIONARY CLIENTS
1. KEY INFORMATION
Name of person dealing (Note 1) Thomas C. Freyman
---
Company dealt in
AbbVie Inc.
---
Class of relevant security to which the US$0.01 Common Stock
dealings being disclosed relate (Note 2)
---
Date
of
dealing
13 February 2020
---
2. INTERESTS AND SHORT POSITIONS
(a) Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)
Long Short
Number (%) Number (%)
(1) Relevant securities 124,414 0.01%
---
(2)
Derivatives
(other
than
options) 0
---
(3) Options and agreements to purchase/sell 0
---
Total 124,414 0.01%
---
(b) Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3)
Class of relevant security: Long Short
---
Number (%) Number (%)
(1) Relevant securities N/A
---
(2)
Derivatives
(other
than
options)
---
(3) Options and agreements to purchase/sell
---
Total
---
Ap10
3. DEALINGS (Note 4)
(a) Purchases and sales
Purchase/sale
Number of relevant securities
Price per unit (Note 5)
---
N/A
---
(b) Derivatives transactions (other than options transactions)
Product name,
Nature of transaction
Number of relevant securities
Price per unit
e.g.
CFD
(Note 6)
(Note 7)
(Note 5)
---
N/A
---
(c) Options transactions in respect of existing relevant securities
(i) Writing, selling, purchasing or varying
Product Writing,
selling, Number
of
name, securities
Exercise Type,
e.g. Expiry Option
money
e.g. to
which
call the
option
option
purchasing,
price
American,
date
paid/received
varying etc.
relates (Note 7)
European etc.
per unit (Note 5)
---
N/A
---
(ii) Exercising
Product name,
Number of securities
Exercise price per
e.g.
call
option unit (Note 5)
---
Stock Options
23,705 shares of common stock
US$29.23
---
(d) Other dealings (including transactions in respect of new securities) (Note 4)
Nature
of
Details Price
per
transaction
unit
(Note 8) (if applicable) (Note 5)
---
N/A
---
Ap11
4. OTHER INFORMATION
Agreements, arrangements or understandings relating to options or derivatives
Full details of any agreement,
arrangement or understanding between
the person disclosing and any other
person relating to the voting rights
of any relevant securities under any
option referred to on this form or
relating to the voting rights or
future acquisition or disposal of any
relevant securities to which any
derivative referred to on this form is
referenced. If none, this should be
stated.
---
N/A
---
Is a Supplemental Form 8 attached? (Note 9) NO
Date of disclosure
13 February 2020
---
Contact
name Manisha Narasimhan, PhD
---
Telephone
number
+ 1 862 261 7162
---
Name
of
offeree/offeror
with
which Allergan plc (NYSE: AGN)
acting
in
concert
---
Specify category and nature of Director of Allergan plc
acting in concert status
---
View original content to download multimedia:http://www.prnewswire.com/news-releases/announcement-under-rule-8-1a-of-the-irish-takeover-rules-dealings-by-offerors-offerees-or-parties-acting-in-concert-with-them-for-themselves-or-for-discretionary-clients-301005072.html
SOURCE Allergan plc
